Discovery of Novel Multivalent/Multifunctional Ligands With µ/d Opioid Agonist (µ-Preferring)/neurokinin 1 (Nk1) Antagonist Activities for the Treatment of PainTechnology #ua15-049
Questions about this technology? Ask a Technology Manager
The present invention is a novel peptide used in the treatment of chronic pain with opioid therapy with a reduction of unwanted side effect such as mental clouding, nausea and emesis, and constipation. These peptide-based ligands are able to interact with CNS receptors separately to produce a higher analgesic effect with no opioid-induced tolerance.
Approximately 1.5 billion people worldwide suffer from chronic pain. Acute and chronic pain among military personnel and veterans is particularly prevalent, with some studies showing greater than 80% of Operation Enduring Freedom and Operation Iraqi Freedom vets suffering from chronic pain. Additionally, almost 30% of veterans seek treatment for chronic pain. Opioids are currently the primary treatment option for veterans suffering from chronis pain due to severe injuries, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI). The opioid therapy is accompanied with serious unwanted effects that makes the patient’s life miserable.
This invention may be used to treat pain, especially chronic pain.
This invention has been demonstrated to be outstanding in several fields, such as:
• Longer In-vitro Metabolic stability
• Higher Lipophilicity
• Better Biological profiles
• Better synergistic effect
Giri, Aswini, Hruby, Victor
Licensing Manager, College of Science
University of Arizona, Tech Launch Arizona
TLA Ofc: 580-626-1557
UA ID: UA15-049